Adenosine Receptor A3-Pipeline Review H2 2018
Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 (ADORA3)-Pipeline Re
(EMAILWIRE.COM, October 06, 2018 ) The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 1, 7, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Oncology, Ophthalmology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Male Health, Metabolic Disorders, Musculoskeletal Disorders, Respiratory and Toxicology which include indications Glaucoma, Non-Alcoholic Steatohepatitis (NASH), Rheumatoid Arthritis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arthritis, Asthma, Atopic Dermatitis (Atopic Eczema), Chemotherapy Induced Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Melanoma, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Ocular Hypertension, Open-Angle Glaucoma, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Pulmonary Fibrosis and Ulcerative Colitis.
Get sample copy of report at: https://www.reportsweb.com/inquiry&RW00012265450/sample
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Enquire about report at: https://www.reportsweb.com/inquiry&RW00012265450/buying
Scope
-The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
-The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
-The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
Get sample copy of report at: https://www.reportsweb.com/inquiry&RW00012265450/sample
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Enquire about report at: https://www.reportsweb.com/inquiry&RW00012265450/buying
Scope
-The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
-The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
-The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results